• Search Research Projects
  • Search Researchers
  • How to Use
  1. Back to previous page

Anti-tumor mechanism of soluble form of sialic acid-recognizing protein, Siglec-9

Research Project

Project/Area Number 26450398
Research Category

Grant-in-Aid for Scientific Research (C)

Allocation TypeMulti-year Fund
Section一般
Research Field Veterinary medical science
Research InstitutionTottori University

Principal Investigator

Tomioka Yukiko  鳥取大学, 農学部, 准教授 (50374674)

Co-Investigator(Kenkyū-buntansha) 森松 正美  北海道大学, 獣医学研究科, 准教授 (70241370)
小野 悦郎  九州大学, 医学研究院, 教授 (00160903)
Research Collaborator TAKEUCHI Takashi  
Project Period (FY) 2014-04-01 – 2017-03-31
Project Status Completed (Fiscal Year 2016)
Budget Amount *help
¥5,070,000 (Direct Cost: ¥3,900,000、Indirect Cost: ¥1,170,000)
Fiscal Year 2016: ¥910,000 (Direct Cost: ¥700,000、Indirect Cost: ¥210,000)
Fiscal Year 2015: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
Fiscal Year 2014: ¥2,340,000 (Direct Cost: ¥1,800,000、Indirect Cost: ¥540,000)
Keywords疾患モデルマウス / 病態 / 腫瘍 / シアル酸認識レクチン / ムチン / トランスジェニックマウス / 疾患モデル動物 / 腫瘍免疫 / シアル酸結合レクチン / 糖タンパク質 / 乳癌 / 卵巣癌 / 抗病性動物 / 発生工学
Outline of Final Research Achievements

It was revealed that proliferation and malignant transformation of MUC1-positive tumor were prevented in the transgenic mice expressing a soluble form of sialic acid-binding immunoglobulin-like lectin 9 (sSiglec-9). In addition, it was suggested that this anti-tumor mechanism indirectly acted through the immune system of the host. On the other hand, sSiglec-9 acivated a proliferation of MUC16-positive tumor rather than inhibited, surprisingly. According to the above results, it was shown Siglec-9 interacted with the mucin expressed in tumor and to participate in a tumor proliferation and malignant transformation. These knowledge make the beginning to found the molecular targeted therapy for cancers through Siglec-9.

Report

(4 results)
  • 2016 Annual Research Report   Final Research Report ( PDF )
  • 2015 Research-status Report
  • 2014 Research-status Report
  • Research Products

    (3 results)

All 2016 2014

All Journal Article (2 results) (of which Peer Reviewed: 2 results,  Acknowledgement Compliant: 2 results,  Open Access: 1 results) Presentation (1 results)

  • [Journal Article] A soluble form of Siglec-9 provides a resistance against Group B Streptococcus (GBS) infection in transgenic mice2016

    • Author(s)
      Saito M, Yamamoto S, Ozaki K, Tomioka Y, Suyama H, Morimatsu M, Nishijima KI, Yoshida SI, Ono E.
    • Journal Title

      Microb Pathog

      Volume: 99 Pages: 106-110

    • Related Report
      2016 Annual Research Report
    • Peer Reviewed / Acknowledgement Compliant
  • [Journal Article] A soluble form of Siglec-9 provides an antitumor benefit against mammary tumor cells expressing MUC1 in transgenic mice.2014

    • Author(s)
      Tomioka Y, Morimatsu M, Nishijima K, Usui T, Yamamoto S, Suyama H, Ozaki K, Ito T, Ono E.
    • Journal Title

      Biochem Biophys Res Commun

      Volume: 450 Issue: 1 Pages: 532-537

    • DOI

      10.1016/j.bbrc.2014.06.009

    • Related Report
      2014 Research-status Report
    • Peer Reviewed / Open Access / Acknowledgement Compliant
  • [Presentation] シアル酸結合レクチンSiglec-9可溶型分子はMUC1発現腫瘍の増殖を抑制する2014

    • Author(s)
      富岡幸子、森松正美、西島謙一、笛吹達史、山本沙代、八木田晴香、尾崎絹代、伊藤壽啓、小野悦郎
    • Organizer
      第157回日本獣医学会学術集会
    • Place of Presentation
      北海道大学
    • Year and Date
      2014-09-11
    • Related Report
      2014 Research-status Report

URL: 

Published: 2014-04-04   Modified: 2018-03-22  

Information User Guide FAQ News Terms of Use Attribution of KAKENHI

Powered by NII kakenhi